Treatment of Stenotrophomonas malthophilia bloodstream infections from guidance to real life: multicenter retrospective cohort study
Abstract
OBJECTIVES: Infectious Diseases Society of America guidance recommend the use of combination therapy (CT) for the treatment of Stenotrophomonas maltophilia (SM) infections. The aims of our study are to describe therapeutical management of patients with SM bloodstream infections (SM-BSI) and to evaluate the impact of antibiotic CT compared to monotherapy (MT) on 30-days mortality.
METHODS: Multicenter, retrospective study of patients with SM-BSI hospitalized in 14 centers between January 2021-December 2022. Multivariable logistic regression analysis was performed to assess the risk factors for 30-days mortality including CT therapy as main exposure. To address potential confounding, an inverse probability of treatment weighting (IPTW) approach was used.
RESULTS: 64 patients with SM-BSI analyzed: 32 (50 %) male, median age of 65 years (IQR: 55-75). MT was administered in 49 patients (76.6 %) and CT in 15 (23.4 %). Trimethoprim/sulphamethoxazole was the most frequent drug used in both MT and CT. Levofloxacin was the second preferred MT. Patients receiving CT were more frequently admitted in ICU with septic shock at BSI onset. At multivariable analysis, septic shock (OR: 7.65, 95 %CI: 1.32-44.48, p = 0.023) and haematological malignancies (OR: 6.82, 95 %CI: 1.50-30.88, p = 0.013) were independent risk factors for 30-day mortality. Using an IPTW-based multivariable analysis, CT showed a non-significant trend toward a protective effect on 30-day mortality (OR: 0.88; 95 % CI:…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 64 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.